Wongsurakiat P.Rattanawongpaibul A.Limsukon A.Chiewchalermsri C.Wiwatcharagoses K.Kornthatchapong K.Saiphoklang N.Sanguanwit P.Domthong P.Kawamatawong T.Sewatanon T.Reechaipichitkul W.Maneechotesuwan K.Mahidol University2024-04-162024-04-162024-01-01Journal of Asthma (2024)02770903https://repository.li.mahidol.ac.th/handle/20.500.14594/98003Objective: This study investigated the utilization of nebulized budesonide for acute asthma and COPD exacerbations as well as for maintenance therapy in adults. Data Sources: We conducted a search on PubMed for nebulized budesonide treatment. Selected Studies: Selecting all English-language papers that utilize Mesh phrases "asthma," "COPD," "budesonide," "nebulized," "adult," "exacerbation," and "maintenance" without temporal restrictions, and narrowing down to clinical research such as RCTs, observational studies, and real-world studies. Results: Analysis of 25 studies was conducted to assess the effectiveness of nebulized budesonide in asthma (n = 10) and COPD (n = 15). The panel in Thailand recommended incorporating nebulized budesonide as an additional or alternative treatment option to the standard of care and systemic corticosteroids (SCS) based on the findings. Conclusion: Nebulized budesonide is effective and well-tolerated in treating asthma and COPD, with less systemic adverse effects compared to systemic corticosteroids. High-dose nebulized budesonide can enhance clinical outcomes for severe and mild exacerbations with slow systemic corticosteroid response. Nebulized budesonide can substitute systemic corticosteroids in some situations.MedicineReviewSCOPUS10.1080/02770903.2024.23348972-s2.0-851899663241532430338527278